462068-45-7

Usage

Uses

Used in Pharmaceutical Industry:
AMPP is used as a reagent in chemical synthesis for the production of various drugs. Its unique structure, containing both an amino group and a phenyl group, allows it to be incorporated into a wide range of drug molecules, enhancing their therapeutic properties.
Used in Research Applications:
AMPP is also used in research applications due to its ability to act as a building block for the creation of new compounds. Researchers and chemists in various fields are interested in exploring its potential applications and properties, which may lead to the development of innovative pharmaceuticals and other chemical products.

InChI:InChI=1/C13H19N3O2/c14-11-1-3-12(4-2-11)15-13(17)5-6-16-7-9-18-10-8-16/h1-4H,5-10,14H2,(H,15,17)

Upstream product

• 19313-88-3 3-chloro-N-(4-nitrophenyl)propanamide 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 1191091-11-8 N₄,N₅-bis(4-(3-(morpholino-4-yl)propanamido)phenyl)-9,10-dihydro-9-oxoacridine-4,5-dicarboxamide 
• 1446421-17-5 N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-3-morpholinopropanamide 
• 1094648-03-9 1,3-bis(3-(1-(4-(3-(morpholin-4-yl)propanamido)phenyl)-1H-1,2,3-triazol-4-yl)phenyl)urea 
• 1070978-58-3 1,3-bis(3-(4-(3-(morpholino)propanamido)phenylcarbamoyl)phenyl)urea 
• 1070979-32-6 N-(4-azidophenyl)-3-(morpholin-4-yl)propanamide 

Relevant academic research and scientific papers

Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach

A series of new, water-soluble phenyl N-mustard-benzenealkylamide conjugates containing hydrophilic ω-dialkylaminoalkylamide or ω-cyclic aminoalkylamide moieties were synthesized via a bioisostere approach. These compounds have a broad spectrum of antitumor activity against a panel of human tumor cell lines. Of these derivatives, compound 18b effectively suppressed the growth of colon cancer (HCT-116), prostate cancer (PC3), and lung cancer (H460) xenografts. The growth of HCT-116 xenografts was almost completely suppressed when co-treated with compound 18b and 5-fluorouracil. Furthermore, compound 18b can induce DNA cross-linking and cell-cycle arrest at the G2/M phase. Early preclinical studies, including pharmacokinetics in rats, inhibition of the hERG, and 14 days of acute intravenous injection toxicity, suggest that compound 18b is a promising candidate for further preclinical studies.

Design, synthesis and evaluation of 4,5-di-substituted acridone ligands with high G-quadruplex affinity and selectivity, together with low toxicity to normal cells

A series of 4,5-di-substituted acridones have been designed and synthesized. Several compounds show high affinity for telomeric G-quadruplex DNA in classical and competition FRET assays, together with low duplex DNA affinity, although they do not show activity in a telomerase assay or evidence of telomere shortening. They have low toxicity against a panel of cancer cell lines and a normal human fibroblast line, and produce potent senescence-based long-term growth arrest in the MCF7 and A549 cancer cell lines.

Rational design of substituted diarylureas: A scaffold for binding to G-quadruplex motifs

The design and synthesis of a series of urea-based nonpolycyclic aromatic ligands with alkylaminoanilino side chains as telomeric and genomic G-quadruplex DNA interacting agents are described. Their interactions with quadruplexes have been examined by means of fluorescent resonance energy transfer melting, circular dichroism, and surface plasmon resonance-based assays. These validate the design concept for such urea-based ligands and also show that they have significant selectivity over duplex DNA, as well as for particular G-quadruplexes. The ligand-quadruplex complexes were investigated by computational molecular modeling, providing further information on structure-activity relationships. Preliminary biological studies using short-term cell growth inhibition assays show that some of the ligands have cancer cell selectivity, although they appear to have low potency for intracellular telomeric G-quadruplex structures, suggesting that their cellular targets may be other, possibly oncogene-related quadruplexes.

UREYLENE DERIVATIVES

The invention concerns compounds of Formula (I) or a salt, solvate or pro-drug thereof. The compounds may be used in therapy, particularly anti-cancer therapy.

Click chemistry assembly of G-quadruplex ligands incorporating a diarylurea scaffold and triazole linkers

A series of diarylurea ligands were designed to interact selectively with G-quadruplexes and were synthesised using copper(I) catalysed 'click' chemistry to incorporate the 1,4-substituted 1,2,3-triazole ring into the core of the ligands; the optimal ligands demonstrate a high degree of selective telomeric G-quadruplex stabilisation and are not cytotoxic in several cancer cell lines. The Royal Society of Chemistry.